Exchange: NASDAQ·Updated 04:20 PM EDT
News
all
press releases
Does Telix Pharmaceuticals Limited (TLX) Have the Potential to Rally 86.17% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 86.2% in Telix Pharmaceuticals Limited (TLX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks
More News
Telix Pharmaceuticals Q2 Revenue Climbs Boosted By Precision Medicine Business
(RTTNews) - Telix Pharmaceuticals Limited (TLX), a radiopharmaceutical company, reported a rise in revenue for the second quarter, helped by the increased revenue from the precision medicine business...
Nasdaq News: Markets
Telix Pharmaceuticals Limited (NASDAQ:TLX) Receives Average Rating of "Moderate Buy" from Analysts
Shares of Telix Pharmaceuticals Limited (NASDAQ:TLX - Get Free Report) have been given an average recommendation of "Moderate Buy" by the nine research firms that are presently covering the stock...
MarketBeat
Telix Pharmaceuticals Webinar Highlights Next-Gen PSMA Therapy, OPTIMAL-PSMA Enrollment Nears End
Telix Pharmaceuticals (NASDAQ:TLX) hosted an educational webinar outlining its next-generation prostate-specific membrane antigen (PSMA) radiopharmaceutical strategy, with management and a clinical...
MarketBeat
Regeneron Boosts Cancer Pipeline Through Telix Collaboration
Regeneron teams up with Telix in a 50/50 radiopharma deal, betting on next-gen cancer therapies to expand its oncology pipeline and long-term growth.
Zacks
Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down - What's Next?
Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down - Time to Sell...
MarketBeat
Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Up - Should You Buy?
Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Up - Here's Why...
MarketBeat
Wedbush Reaffirms Outperform Rating for Telix Pharmaceuticals (NASDAQ:TLX)
Wedbush reissued an "outperform" rating and set a $22.00 price target on shares of Telix Pharmaceuticals in a report on Monday...
MarketBeat
Telix Pharmaceuticals (NASDAQ:TLX) Given "Buy" Rating at HC Wainwright
HC Wainwright reiterated a "buy" rating and issued a $20.00 price target on shares of Telix Pharmaceuticals in a research report on Monday...
MarketBeat
Regeneron Pharma Partners Telix Pharma To Jointly Develop Radiopharmaceutical Therapies
(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) and Telix Pharmaceuticals Ltd. (TLX, TLX.AX) announced Monday a collaboration to jointly develop and commercialize next generation radiopharmaceutical therapies...
Nasdaq News: Markets

Advertisement|Remove ads.